Sotigalimab by Pyxis Oncology for Glioma: Likelihood of Approval
Sotigalimab is under clinical development by Pyxis Oncology and currently in Phase I for Glioma. According to GlobalData, Phase I drugs for Glioma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData's report assesses how Sotigalimab's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Sotigalimab overviewSotigalimab (APX-005M) is under development for the treatment of renal cell carcinoma, metastatic melanoma, recurrent or refractory primary malignant CNS tumors including newly diagnosed diffuse intrinsic pontine gliomas, anaplastic astrocytoma, pleomorphic sarcoma, liposarcoma, leiomyosarcoma, glioblastoma multiforme, gliosarcoma, anaplastic mixed glioma or fibrillary astrocytoma, metastatic pancreatic ductal adenocarcinoma, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the esophagus or GE junction, urothelial carcinoma, squamous cell carcinoma of the head and neck, rectal adenocarcinoma and other solid tumors with high microsatellite instability status. The drug candidate is administered intravenously and intratumorally. APX-005 is a monoclonal antibody that acts as CD40 agonist. It is developed using a proprietary mutational lineage guided (MLG) humanization technology and APXiMAB discovery platform It was under development for the treatment of non-small cell lung cancer, melanoma, epithelial ovarian, fallopian tube or primary peritoneal cancer.Pyxis Oncology overviewPyxis Oncology is an immuno-oncology company that develops antibody drug conjugates (ADC) and immunotherapies for cancer. It is investigating PYX-201 to treat solid tumors; PYX-202 program to treat soft tissue sarcoma; and PYX-203 drug against myelodysplastic syndromes (MDS) and acute myeloid leukemia. The company utilizes its proprietary flexible antibody conjugation technology (FACT) platform to develop ADCs. Pyxis Oncology’s platform technology analyses promising tumor targets and acquire highly specific antibodies to these tumor targets. It carries out research and development with pharmaceutical and biotech companies to develop innovative medicines. Pyxis Oncology is headquartered in Cambridge, Massachusetts, the US. For a complete picture of Sotigalimab's drug-specific PTSR and LoA scores, buy the report here.
Sotigalimab is under clinical development by Pyxis Oncology and currently in Phase I for Glioma.
What's Your Reaction?
